Hypoxia and antitumor CD8+ T cells: An incompatible alliance?

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Vuillefroy de Silly, Romain ^a,b   Dietrich, Pierre Yves ^a   Walker, Paul R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cancer; CD8+ T cell; CTL; hypoxia; normoxia; oxygen; physioxia; tumor

Indexed keywords

CD137 ANTIGEN; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; T LYMPHOCYTE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR IMMUNITY; CYTOLYSIS; HUMAN; HYPOXIA; IMMUNE RESPONSE; IN VITRO STUDY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 84999663611     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1232236     Document Type: Review

References (74)

1. Ivanovic Z. Hypoxia or in situ normoxia:The stem cell paradigm. J Cell Physiol 2009; 219:271-5; PMID:19160417; http://dx.doi.org/10.1002/jcp.21690
2. McNamee EN, Korns Johnson D, Homann D, Clambey ET. Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunol Res 2013; 55:58-70; PMID:22961658; http://dx.doi.org/10.1007/s12026-012-8349-8
3. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 2011; 15:1239-53; PMID:21251211; http://dx.doi.org/10.1111/j.1582-4934.2011.01258.x
4. Eltzschig HK, Carmeliet P. Hypoxia and inflammation. N Engl J Med 2011; 364:656-65; PMID:21323543; http://dx.doi.org/10.1056/NEJMra0910283
5. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KS, Chapman JD, Eckelman WC, Fyles AW, Giaccia AJ, et al. Hypoxia:importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006; 82:699-757; PMID:17118889; http://dx.doi.org/10.1080/09553000601002324
6. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors:association with angiogenesis, invasion, and progression. Cancer 2000; 88:2606-18; PMID:10861440; http://dx.doi.org/10.1002/1097-0142(20000601)88:11%3c2606::AID-CNCR25%3e3.0.CO;2-W
7. Scholz CC, Taylor CT. Targeting the HIF pathway in inflammation and immunity. Curr Opin Pharmacol 2013; 13:646-53; PMID:23660374; http://dx.doi.org/10.1016/j.coph.2013.04.009
8. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15:501-13; PMID:19477429; http://dx.doi.org/10.1016/j.ccr.2009.03.018
9. Harris AL. Hypoxia–a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47; PMID:11902584; http://dx.doi.org/10.1038/nrc704
10. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29:625-34; PMID:19946328; http://dx.doi.org/10.1038/onc.2009.441
11. Noman MZ, Hasmim M, Messai Y, Terry S, Kieda C, Janji B, Chouaib S. Hypoxia:a key player in antitumor immune response. A review in the theme:Cellular responses to hypoxia. Am J Physiol Cell Physiol 2015; 309:C569-79; PMID:26310815; http://dx.doi.org/10.1152/ajpcell.00207.2015
12. Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress:obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 2016; PMID:27345407; http://dx.doi.org/10.1038/onc.2016.225
13. Kumar V, Gabrilovich DI. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 2014; 143:512-9; PMID:25196648; http://dx.doi.org/10.1111/imm.12380
14. Winning S, Fandrey J. Dendritic cells under hypoxia:How oxygen shortage affects the linkage between innate and adaptive immunity. J Immunol Res 2016; 2016:5134329; PMID:26966693; http://dx.doi.org/10.1155/2016/5134329
15. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, et al. Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 2011; 146:772-84; PMID:21871655; http://dx.doi.org/10.1016/j.cell.2011.07.033
16. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; http://dx.doi.org/10.1038/nrc1187
17. Lolkema MP, Gervais ML, Snijckers CM, Hill RP, Giles RH, Voest EE, Ohh M. Tumor suppression by the von Hippel-Lindau protein requires phosphorylation of the acidic domain. J Biol Chem 2005; 280:22205-11; PMID:15824109; http://dx.doi.org/10.1074/jbc.M503220200
18. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, et al. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci U S A 2006; 103:18154-9; PMID:17114296; http://dx.doi.org/10.1073/pnas.0602235103
19. Finlay DK, Rosenzweig E, Sinclair LV, Feijoo-Carnero C, Hukelmann JL, Rolf J, Panteleyev AA, Okkenhaug K, Cantrell DA. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med 2012; 209:2441-53; PMID:23183047; http://dx.doi.org/10.1084/jem.20112607
20. Doedens AL, Phan AT, Stradner MH, Fujimoto JK, Nguyen JV, Yang E, Johnson RS, Goldrath AW. Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat Immunol 2013; 14:1173-82; PMID:24076634; http://dx.doi.org/10.1038/ni.2714
21. Vuillefroy de Silly R, Ducimetiere L, Yacoub Maroun C, Dietrich PY, Derouazi M, Walker PR. Phenotypic switch of CD8(+) T cells reactivated under hypoxia toward IL-10 secreting, poorly proliferative effector cells. Eur J Immunol 2015; 45:2263-75; PMID:25929785; http://dx.doi.org/10.1002/eji.201445284
22. Chang CH, Curtis JD, Maggi LB, Jr., Faubert B, Villarino AV, O'Sullivan D, Huang SC, van der Windt GJ, Blagih J, Qiu J, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 2013; 153:1239-51; PMID:23746840; http://dx.doi.org/10.1016/j.cell.2013.05.016
23. Zumwalde NA, Domae E, Mescher MF, Shimizu Y. ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation. J Immunol 2013; 191:3681-93; PMID:23997225; http://dx.doi.org/10.4049/jimmunol.1201954
24. Arsham AM, Howell JJ, Simon MC. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J Biol Chem 2003; 278:29655-60; PMID:12777372; http://dx.doi.org/10.1074/jbc.M212770200
25. Park EC, Ghose P, Shao Z, Ye Q, Kang L, Xu XZ, Powell-Coffman JA, Rongo C. Hypoxia regulates glutamate receptor trafficking through an HIF-independent mechanism. EMBO J 2012; 31:1379-93; PMID:22252129; http://dx.doi.org/10.1038/emboj.2011.499
26. Atkuri KR, Herzenberg LA. Culturing at atmospheric oxygen levels impacts lymphocyte function. Proc Natl Acad Sci U S A 2005; 102:3756-9; PMID:15738407; http://dx.doi.org/10.1073/pnas.0409910102
27. Atkuri KR, Herzenberg LA, Niemi AK, Cowan T. Importance of culturing primary lymphocytes at physiological oxygen levels. Proc Natl Acad Sci USA 2007; 104:4547-52; PMID:17360561; http://dx.doi.org/10.1073/pnas.0611732104
28. Caldwell CC, Kojima H, Lukashev D, Armstrong J, Farber M, Apasov SG, Sitkovsky MV. Differential effects of physiologically relevant hypoxic conditions on T lymphocyte development and effector functions. J Immunol 2001; 167:6140-9; PMID:11714773; http://dx.doi.org/10.4049/jimmunol.167.11.6140
29. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998; 16:201-23; PMID:9597129; http://dx.doi.org/10.1146/annurev.immunol.16.1.201
30. Buck MD, O'Sullivan D, Pearce EL. T cell metabolism drives immunity. J Exp Med 2015; 212:1345-60; PMID:26261266; http://dx.doi.org/10.1084/jem.20151159
31. Zuckerberg AL, Goldberg LI, Lederman HM. Effects of hypoxia on interleukin-2 mRNA expression by T lymphocytes. Crit Care Med 1994; 22:197-203; PMID:8306676; http://dx.doi.org/10.1097/00003246-199402000-00008
32. Krieger JA, Landsiedel JC, Lawrence DA. Differential in vitro effects of physiological and atmospheric oxygen tension on normal human peripheral blood mononuclear cell proliferation, cytokine and immunoglobulin production. Int J Immunopharmacol 1996; 18:545-52; PMID:9080248; http://dx.doi.org/10.1016/S0192-0561(96)00057-4
33. Naldini A, Carraro F, Silvestri S, Bocci V. Hypoxia affects cytokine production and proliferative responses by human peripheral mononuclear cells. J Cell Physiol 1997; 173:335-42; PMID:9369946; http://dx.doi.org/10.1002/(SICI)1097-4652(199712)173:3%3c335::AID-JCP5%3e3.0.CO;2-O
34. Makino Y, Nakamura H, Ikeda E, Ohnuma K, Yamauchi K, Yabe Y, Poellinger L, Okada Y, Morimoto C, Tanaka H. Hypoxia-inducible factor regulates survival of antigen receptor-driven T cells. J Immunol 2003; 171:6534-40; PMID:14662854; http://dx.doi.org/10.4049/jimmunol.171.12.6534
35. Roman J, Rangasamy T, Guo J, Sugunan S, Meednu N, Packirisamy G, Shimoda LA, Golding A, Semenza G, Georas SN. T-cell activation under hypoxic conditions enhances IFN-gamma secretion. Am J Respir Cell Mol Biol 2010; 42:123-8; PMID:19372249; http://dx.doi.org/10.1165/rcmb.2008-0139OC
36. + T lymphocytes. Immunol Lett 2010; 131:97-105; PMID:20206208; http://dx.doi.org/10.1016/j.imlet.2010.02.008
37. Conforti L, Petrovic M, Mohammad D, Lee S, Ma Q, Barone S, Filipovich AH. Hypoxia regulates expression and activity of Kv1.3 channels in T lymphocytes:a possible role in T cell proliferation. J Immunol 2003; 170:695-702; PMID:12517930; http://dx.doi.org/10.4049/jimmunol.170.2.695
38. Larbi A, Zelba H, Goldeck D, Pawelec G. Induction of HIF-1alpha and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. J Leukoc Biol 2010; 87:265-73; PMID:19892848; http://dx.doi.org/10.1189/jlb.0509304
39. Gaber T, Tran CL, Schellmann S, Hahne M, Strehl C, Hoff P, Radbruch A, Burmester GR, Buttgereit F. Pathophysiological hypoxia affects the redox state and IL-2 signalling of human CD4+ T cells and concomitantly impairs survival and proliferation. Eur J Immunol 2013; 43:1588-97; PMID:23519896; http://dx.doi.org/10.1002/eji.201242754
40. Ohta A, Madasu M, Subramanian M, Kini R, Jones G, Chouker A, Sitkovsky M. Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible. Int Immunol 2014; 26:83-91; PMID:24150242; http://dx.doi.org/10.1093/intimm/dxt045
41. Dimeloe S, Mehling M, Frick C, Loeliger J, Bantug GR, Sauder U, Fischer M, Belle R, Develioglu L, Tay S, et al. The immune-metabolic basis of effector memory CD4+ T cell function under hypoxic conditions. J Immunol 2016; 196:106-14; PMID:26621861; http://dx.doi.org/10.4049/jimmunol.1501766
42. Xu Y, Chaudhury A, Zhang M, Savoldo B, Metelitsa LS, Rodgers J, Yustein JT, Neilson JR, Dotti G. Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. J Clin Invest 2016; 126(7):2678-2688; PMID:27294526; http://dx.doi.org/10.1172/JCI85834
43. Lukashev D, Klebanov B, Kojima H, Grinberg A, Ohta A, Berenfeld L, Wenger RH, Sitkovsky M. Cutting edge:hypoxia-inducible factor 1alpha and its activation-inducible short isoform I.1 negatively regulate functions of CD4+ and CD8+ T lymphocytes. J Immunol 2006; 177:4962-5; PMID:17015677; http://dx.doi.org/10.4049/jimmunol.177.8.4962
44. Lukashev D, Sitkovsky M. Preferential expression of the novel alternative isoform I.3 of hypoxia-inducible factor 1alpha in activated human T lymphocytes. Human immunology 2008; 69:421-5; PMID:18638657; http://dx.doi.org/10.1016/j.humimm.2008.05.004
45. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H, Pietras A, Vallon-Christersson J, Borg A, Gradin K, et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma:HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10:413-23; PMID:17097563; http://dx.doi.org/10.1016/j.ccr.2006.08.026
46. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha:sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2012; 12:9-22; PMID:22169972; http://dx.doi.org/10.1038/nrc3183
47. Hanna SC, Krishnan B, Bailey ST, Moschos SJ, Kuan PF, Shimamura T, Osborne LD, Siegel MB, Duncan LM, O'Brien ET, 3rd et al. HIF1alpha and HIF2alpha independently activate SRC to promote melanoma metastases. J Clin Invest 2013; 123:2078-93; PMID:23563312; http://dx.doi.org/10.1172/JCI66715
48. Nakagawa Y, Negishi Y, Shimizu M, Takahashi M, Ichikawa M, Takahashi H. Effects of extracellular pH and hypoxia on the function and development of antigen-specific cytotoxic T lymphocytes. Immunol Lett 2015; 167:72-86; PMID:26209187; http://dx.doi.org/10.1016/j.imlet.2015.07.003
49. Haddad H, Windgassen D, Ramsborg CG, Paredes CJ, Papoutsakis ET. Molecular understanding of oxygen-tension and patient-variability effects on ex vivo expanded T cells. Biotechnol Bioeng 2004; 87:437-50; PMID:15286980; http://dx.doi.org/10.1002/bit.20166
50. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, Finkelstein SE, Theoret MR, Rosenberg SA, Restifo NP. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest 2005; 115:1616-26; PMID:15931392; http://dx.doi.org/10.1172/JCI24480
51. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17:1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446
52. Sukumar M, Liu J, Mehta GU, Patel SJ, Roychoudhuri R, Crompton JG, Klebanoff CA, Ji Y, Li P, Yu Z, et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metabolism 2016; 23:63-76; PMID:26674251; http://dx.doi.org/10.1016/j.cmet.2015.11.002
53. Noman MZ, Buart S, Van Pelt J, Richon C, Hasmim M, Leleu N, Suchorska WM, Jalil A, Lecluse Y, El Hage F, et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol 2009; 182:3510-21; PMID:19265129; http://dx.doi.org/10.4049/jimmunol.0800854
54. Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, Buart S, Berchem G, Romero P, Mami-Chouaib F, et al. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res 2011; 71:5976-86; PMID:21810913; http://dx.doi.org/10.1158/0008-5472.CAN-11-1094
55. Noman MZ, Buart S, Romero P, Ketari S, Janji B, Mari B, Mami-Chouaib F, Chouaib S. Hypoxia-inducible miR-210 regulates the susceptibility of tumor cells to lysis by cytotoxic T cells. Cancer Res 2012; 72:4629-41; PMID:22962263; http://dx.doi.org/10.1158/0008-5472.CAN-12-1383
56. Baginska J, Viry E, Berchem G, Poli A, Noman MZ, van Moer K, Medves S, Zimmer J, Oudin A, Niclou SP, et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc Natl Acad Sci U S A 2013; 110:17450-5; PMID:24101526; http://dx.doi.org/10.1073/pnas.1304790110
57. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 2007; 179:845-53; PMID:17617575; http://dx.doi.org/10.4049/jimmunol.179.2.845
58. Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, Validire P, Besse B, Mami-Chouaib F. CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol 2015; 194:3475-86; PMID:25725111; http://dx.doi.org/10.4049/jimmunol.1402711
59. Steinbach K, Vincenti I, Kreutzfeldt M, Page N, Muschaweckh A, Wagner I, Drexler I, Pinschewer D, Korn T, Merkler D. Brain-resident memory T cells represent an autonomous cytotoxic barrier to viral infection. J Exp Med 2016; PMID:27377586; http://dx.doi.org/10.1084/jem.20151916
60. Thiel M, Caldwell CC, Kreth S, Kuboki S, Chen P, Smith P, Ohta A, Lentsch AB, Lukashev D, Sitkovsky MV. Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One 2007; 2:e853; PMID:17786224; http://dx.doi.org/10.1371/journal.pone.0000853
61. Neumann AK, Yang J, Biju MP, Joseph SK, Johnson RS, Haase VH, Freedman BD, Turka LA. Hypoxia inducible factor 1 alpha regulates T cell receptor signal transduction. Proc Natl Acad Sci U S A 2005; 102:17071-6; PMID:16286658; http://dx.doi.org/10.1073/pnas.0506070102
62. Robbins JR, Lee SM, Filipovich AH, Szigligeti P, Neumeier L, Petrovic M, Conforti L. Hypoxia modulates early events in T cell receptor-mediated activation in human T lymphocytes via Kv1.3 channels. J Physiol 2005; 564:131-43; PMID:15677684; http://dx.doi.org/10.1113/jphysiol.2004.081893
63. Clambey ET, McNamee EN, Westrich JA, Glover LE, Campbell EL, Jedlicka P, de Zoeten EF, Cambier JC, Stenmark KR, Colgan SP, et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc Natl Acad Sci USA 2012; 109:E2784-93; PMID:22988108; http://dx.doi.org/10.1073/pnas.1202366109
64. Shehade H, Acolty V, Moser M, Oldenhove G. Cutting edge:Hypoxia-inducible factor 1 negatively regulates Th1 function. J Immunol 2015; 195:1372-6; PMID:26179900; http://dx.doi.org/10.4049/jimmunol.1402552
65. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004; 22:657-82; PMID:15032592; http://dx.doi.org/10.1146/annurev.immunol.22.012703.104731
66. Sena LA, Li S, Jairaman A, Prakriya M, Ezponda T, Hildeman DA, Wang CR, Schumacker PT, Licht JD, Perlman H, et al. Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 2013; 38:225-36; PMID:23415911; http://dx.doi.org/10.1016/j.immuni.2012.10.020
67. Kesarwani P, Murali AK, Al-Khami AA, Mehrotra S. Redox regulation of T-cell function:from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal 2013; 18:1497-534; PMID:22938635; http://dx.doi.org/10.1089/ars.2011.4073
68. Bell EL, Klimova TA, Eisenbart J, Moraes CT, Murphy MP, Budinger GR, Chandel NS. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J Cell Biol 2007; 177:1029-36; PMID:17562787; http://dx.doi.org/10.1083/jcb.200609074
69. Palazon A, Teijeira A, Martinez-Forero I, Hervas-Stubbs S, Roncal C, Penuelas I, Dubrot J, Morales-Kastresana A, Perez-Gracia JL, Ochoa MC, et al. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011; 71:801-11; PMID:21266358; http://dx.doi.org/10.1158/0008-5472.CAN-10-1733
70. Palazon A, Martinez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Penuelas I, Hervas-Stubbs S, Rouzaut A, et al. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2012; 2:608-23; PMID:22719018; http://dx.doi.org/10.1158/2159-8290.CD-11-0314
71. Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting Cancer Immunotherapy with anti-CD137 Antibody Therapy. Clin Cancer Res 2015; 21:3113-20; PMID:25908780; http://dx.doi.org/10.1158/1078-0432.CCR-15-0263
72. McIntyre A, Harris AL. Metabolic and hypoxic adaptation to anti-angiogenic therapy:a target for induced essentiality. EMBO Mol Med 2015; 7:368-79; PMID:25700172; http://dx.doi.org/10.15252/emmm.201404271
73. Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012; 12:237-51; PMID:22437869; http://dx.doi.org/10.1038/nrc3237
74. Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R, et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 2015; 7:277ra30; PMID:25739764; http://dx.doi.org/10.1126/scitranslmed.aaa1260